VRTX Vertex Pharmaceuticals Incorporated

Vertex Announces 10-Year, $500 Million Corporate Giving Commitment

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced a 10-year, $500 million corporate giving commitment focused on providing patient and caregiver support including access to our medicines; expanding our commitment to science, technology, engineering, arts and math (STEAM) education; developing young physicians and scientists; and investing in our communities. $50 million of this giving will be dedicated to STEAM education, particularly for underserved students and young women. As part of this commitment, the company will establish The Vertex Foundation, a 501(c)(3) organization and long-term source of charitable giving, with an initial contribution of $10 million. The Vertex Foundation will support, among other initiatives, a new dollar-for-dollar matching gifts program to extend the impact of employee donations to qualified non-profit organizations.

In addition, Vertex will extend for another 10 years its successful collaboration with the Boston Public Schools (BPS) to ensure that BPS students continue to have ongoing access to Vertex’s 3,000 square foot learning lab, mentoring and internship opportunities with Vertex scientists and full four-year scholarships to the University of Massachusetts each year.

“Giving back is part of who we are at Vertex – it’s in our DNA,” said Dr. Jeffrey Leiden, President, Chairman and Chief Executive Officer of Vertex. “This new 10-year commitment will provide many more opportunities for Vertex and its employees to make a difference in the lives of people with serious diseases and those living in our communities.”

"For Vertex, innovative ideas that transform lives have never been restricted to lab rooms,” said Congressman Joe Kennedy III. “With this investment in their neighbors, patients, and local students, Vertex can both strengthen their community today and expand our Commonwealth's workforce of tomorrow."

“In Boston, we are lucky to have companies like Vertex stepping up and contributing to our city and our future workforce,” said Boston Mayor Martin J. Walsh. “This commitment will mean thousands of students across the City will continue to have the opportunity to get hands-on experiences in STEAM and see a place for themselves in Boston’s thriving innovation economy.”

Vertex’s corporate giving commitment will focus on the following:

  • The cystic fibrosis (CF) patient community globally, including enabling access to our medicines;
  • STEAM education, focused on underserved students and young women;
  • Developing young physicians and scientists; and
  • Strengthening our local communities, including fostering the innovation ecosystem and supporting youth health and wellness.

The Vertex Foundation will launch in 2018.

About Vertex

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.

Founded in 1989 in Cambridge, Mass., Vertex's headquarters is now located in Boston's Innovation District. Today, the company has research and development sites and commercial offices in the United States, Europe, Canada and Australia. Vertex is consistently recognized as one of the industry's top places to work, including being named to Science magazine's Top Employers in the life sciences ranking for seven years in a row. For additional information and the latest updates from the company, please visit www.vrtx.com.

For Funding Requests please visit https://www.vrtx.com/giving-back.

(VRTX-GEN)

EN
17/10/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vertex Pharmaceuticals Incorporated

Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: August 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Research Team ACF
  • Research Team ACF

KDST + NLSP Combined Core Investment Case 29052025

We consider the merged platform Kadimastem (KDST.TA) + NLS Pharmaceutics (NLSP:NasdaqCM). We provide an investment case analysis and a selection of merged metrics prior to any synergies. The merger creates a cross-platform pre-revenue biotech with lead programs including a proprietary stem-differentiation platform capable of delivering scalable therapies for replacing lost or damaged cells; IsletRx could revolutionize insulin production for Type 1 diabetes (T1D) patients; AstroRx® targets neurod...

Research Team ACF
  • Research Team ACF

ACF Thematic Research Regenerative Medicine Diabetes Treatment & Innov...

Diabetes mellitus, Type 1 (T1D) and Type 2 (T2D, 85-90% of cases), is a USD ~75bn global therapy market. Global economic costs of diabetes may exceed USD1 trn today and USD 450bn in the US, suggesting a pressing global health challenge. Diabetes is a chronic metabolic disorder characterized by high blood sugar levels. In 2024, consensus global estimates suggested there were ~800m adult diabetes sufferers. In 2021, according to the IDF there >530m sufferers globally. For 2027E we modestly forecas...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch